Boehringer Ingelheim KG & Ors v Swingward Ltd [2004] EWCA Civ 757 (17 June 2004)

Boehringer Ingelheim KG & Ors v Swingward Ltd [2004] EWCA Civ 757 (17 June 2004)

The Court determined that significant uncertainties remain regarding the application of the Bristol-Myers Squibb v Paranova conditions to reboxed and overstickered parallel imports, particularly concerning the burden of proof, the scope of the necessity and reputation conditions, and the remedies for procedural breaches. The Court formulated comprehensive questions for reference to the ECJ to resolve these uncertainties and adjourned the appeals pending the ECJ's answers.

Citation
[2004] EWCA Civ 757
Parties
Appellant/claimant: Boehringer Ingelheim KG; Appellant/claimant: Boehringer Ingelheim Pharma GmbH & Co KG; Appellant/claimant: Boehringer Ingelheim Limited; Appellant/claimant/respondent: Glaxo Group Limited; Respondent/claimant: Smithkline Beecham plc; Respondent/claimant: Beecham Group plc; Respondent/claimant: Smithkline and French Laboratories Limited; Respondent/claimant: Eli Lilly and Company; Respondent/defendant: Swingward Limited; Appellant/defendant/respondent: Dowelhurst Limited
Jurisdiction
England and Wales
Judgment Date
17 June 2004
Procedural Posture
Appeal From Chancery Division / Reference to Ecj; Appeals Adjourned Pending ECJ Decision
Outcome
Reference to ECJ; appeals adjourned pending ECJ decision; no order for costs at this stage.
Legal Topics
Trade Marks, Parallel Imports, Repackaging, Burden of Proof, Remedies, Proportionality, Pharmaceuticals
Intellectual Property Law European Union Law Trade Marks Parallel Imports Repackaging Burden of Proof Remedies Proportionality +1 more

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 3 Authorities cited 4 Party arguments 2 Amounts and remedies 1
Sign in to unlock

Parties

Boehringer Ingelheim KG

Appellant/claimant

Boehringer Ingelheim Pharma GmbH & Co KG

Appellant/claimant

Boehringer Ingelheim Limited

Appellant/claimant

Glaxo Group Limited

Appellant/claimant/respondent

Smithkline Beecham plc

Respondent/claimant

Beecham Group plc

Respondent/claimant

Smithkline and French Laboratories Limited

Respondent/claimant

Eli Lilly and Company

Respondent/claimant

Swingward Limited

Respondent/defendant

Dowelhurst Limited

Appellant/defendant/respondent

Procedural Posture

Appeal From Chancery Division / Reference to Ecj; Appeals Adjourned Pending ECJ Decision

Legal Issues

  1. 1 Whether and how the conditions in Bristol-Myers Squibb v Paranova apply to reboxed and overstickered pharmaceutical products imported in parallel within the EEA.
  2. 2 Who bears the burden of proof for compliance with those conditions.
  3. 3 Whether the necessity and reputation conditions apply to the manner and style of repackaging or overstickering.

Ratio Decidendi

The Court determined that significant uncertainties remain regarding the application of the Bristol-Myers Squibb v Paranova conditions to reboxed and overstickered parallel imports, particularly concerning the burden of proof, the scope of the necessity and reputation conditions, and the remedies for procedural breaches. The Court formulated comprehensive questions for reference to the ECJ to resolve these uncertainties and adjourned the appeals pending the ECJ's answers.

Court Disposition

Reference to ECJ; appeals adjourned pending ECJ decision; no order for costs at this stage.

Orders

  • Questions referred to the ECJ as set out in the judgment.
  • Appeals adjourned until result from Europe.